Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report

Lívia Maria Bolsoni, MS; Thiago Dornela Apolinário da Silva, MD; Silvana Maria Quintana, MD, PhD; Margaret de Castro, MD, PhD; José Alexandre Crippa, MD, PhD; Antonio Waldo Zuardi, MD, PhD

ABSTRACT

Introduction: Previous studies have shown attenuated cortisol awakening response in patients with posttraumatic stress disorder (PTSD).

Case Presentation: A 15-year-old girl, a survivor of acute sexual violence, received a 7-day oral treatment with cannabidiol. She was followed-up from the first 24 hours after the event for 6 months, for assessment of the effects of this treatment on the reconsolidation of memories related to the traumatic event.

Discussion: Cannabidiol treatment did not prevent the onset of PTSD. Cortisol awakening responses after the onset of the disorder were attenuated compared with those observed in the same individual before the onset of PTSD, in line with previous evidence from studies comparing groups with and without PTSD.

INTRODUCTION

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), posttraumatic stress disorder (PTSD) is characterized by abnormal behavioral responses resulting from exposure to a major traumatic event. The traumatic event is persistently revived in 1 or more ways, for example, in the form of nightmares or feelings like those experienced during the traumatic event. Also, there is persistent avoidance of stimuli associated with the trauma and persistent symptoms of excitability.

Compared with its previous versions, the DSM-V added a fourth group of symptoms related to negative changes in cognition and mood. These symptoms should last for more than 1 month and be accompanied by considerable distress to the individual.

Results of a recent meta-analysis showed that among people who have been sexually abused, depressive disorders and PTSD were the most prevalent consequences, with 36% of sexually abused people having PTSD throughout their lives and 26% in the last year. Sexual abuse, both in childhood and in adulthood, can have serious consequences for the affected individual, including substance abuse and/or dependence, eating disorders, anxiety, depression, and cognitive consequences.

PTSD could change the activity of the hypothalamic-pituitary-adrenal axis. The cortisol awakening response (CAR) is a way to measure hypothalamic-pituitary-adrenal axis function because cortisol levels are expected to increase after awakening and to reach a peak within 1 hour.

We found 7 previous studies that analyzed the CAR in patients with PTSD. Except for the study by Lindley et al, the other 4 studies that compared CAR levels in patients with PTSD and healthy controls found decreased CAR in patients with PTSD. Also, 2 studies investigated the levels of PTSD symptoms and CAR in patients, and both described an inverse relationship between the severity of PTSD symptoms and CAR. Reduced CAR in patients with PTSD may be related to increased suppression of the hypothalamic-pituitary-adrenal axis, as suggested by evidence showing that the administration of dexamethasone was associated with increased cortisol suppression in patients exposed to trauma (with or without PTSD) compared with healthy controls.

The studies cited above compared the CAR in groups with and without PTSD or correlated levels of PTSD symptoms with CAR measures. In the present case report, we describe the evolution of the CAR before and after the diagnosis of PTSD in the same patient.

We have systematically followed-up a survivor of sexual violence since the first 24 hours after the event for a 6-month period. The objective of this follow-up was to assess whether the administration of cannabidiol (CBD) daily for 1 week beginning 72 hours after the traumatic event, interfered with the consolidation/reconsolidation of memories related to the traumatic event.

CBD is a compound of the plant *Cannabis sativa*, responsible for 40% of the plant composition. This compound is free from the psychoactive effects caused by tetrahydrocannabinol. A series of evidence suggests that CBD, in addition to its anxiolytic effect, was able to interfere in aversive memories. During the processes of consolidation or reconsolidation, memory recall makes stored material labile and susceptible to pharmacologic interference. Evidence in rodents suggests that CBD blocks reconsolidation of an aversive memory in a context-based fear paradigm. Recently, the effect of CBD on extinction learning has been studied in humans, using a Pavlovian fear-conditioning paradigm in healthy volunteers. The results of this study indicate that CBD increased the consolidation of extinction learning, suggesting its potential effect on the extinction of fears learned in anxiety disorders, particularly PTSD.

Author Affiliations

1 Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil
2 Department of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Brazil
3 Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil
4 National Institute of Science and Technology for Translational Medicine, National Council for Scientific and Technological Development, Brasília, Brazil

Corresponding Author

Lívia Maria Bolsoni, MS (livia@usp.br)

Keywords: cannabidiol, cortisol awakening response, memory reconsolidation, posttraumatic stress disorder, PTSD
CASE PRESENTATION

Presenting Concerns

A 15-year-old adolescent girl was referred to an Emergency Department (ED) for survivors of sexual abuse at the University Hospital of the Ribeirão Preto Medical School-University of São Paulo (HCFMRP-USP) in Ribeirão Preto, Brazil, on the same day that she experienced sexual violence by an unknown man. The episode of sexual violence was the only one the patient experienced. The girl was a student, unmarried, and a nonsmoker and belonged to socioeconomic stratum B2 (for example, high school student, middle class, unmarried, and a nonsmoker) according to Brazil’s socioeconomic classification criteria. The presence of organic brain syndromes, psychoactive drug abuse, and other psychiatric disorders was excluded. The recruitment interview for the study occurred while the patient was at the ED, and the procedures ended with an invitation for a more detailed conversation the next day.

The procedures of the present study were developed in parallel to the usual care that female survivors of violence receive in the HCFMRP-USP. This protocol consists of ED care for prophylaxis with contraceptive and antiretroviral methods. After this first approach, the patients are referred to a service of care for survivors of domestic and sexual violence that relies on professionals in the fields of psychiatry, psychology, and social work. In this service, medical and psychosocial treatments are offered for possible consequences of abuse. The Research Ethics Committee of the HCFMRP-USP approved the study (process no. 1398873).

Therapeutic Intervention and Treatment

In the ED, prophylaxis was implemented within 24 hours of the event such as pregnancy prevention and medications for sexually transmitted diseases. In the interview conducted 1 day after the ED (day 1), the patient signed a consent form to participate in the study and completed instruments to assess eligibility and collect baseline data. The instruments were the following: Questionnaire for clinical and demographic evaluation; Mini-Screening of Mental Disorders (Mini-SMD), a screening tool for specific mental disorders in the general population that was developed and validated in Brazil; Structured Clinical Interview for DSM-V (SCID-5-Clinical Version) if results of the Mini-SMD were positive; Posttraumatic Stress Disorder Checklist-5 (PCL-5); State–Trait Anxiety Inventory (STAI-T and STAI-S [State]); and Patient Health Questionnaire-9 (PHQ-9).

After the instruments were completed, the patient received instructions and material for the CAR test to be performed the following night and subsequent morning. For the CAR response test, the participant collected 4 saliva samples. The first sample was collected 48 hours after the traumatic event, at bedtime. On the following day, 3 saliva samples were obtained immediately after spontaneous or alarm-induced awakening, considered as T0 (while still in bed), and 30 and 60 minutes after awakening. Specifically, the patient collected saliva samples at 10 pm and at 6, 6:30, and 7 am on the next day. Material for the CAR test was also collected on day 16 (at 11 pm and 7, 7:30, and 8 am), day 60 (at midnight and 10, 10:30, and 11 am), and day 180 (at 10 pm and 7, 7:30, and 8 am) after the traumatic event.

A behavioral test was performed on day 2 (before completing 72 hours of the traumatic event) and repeated 16 days later. The test was an adaptation of the procedure proposed by Pitman et al, which was shown to generate subjective symptoms and physiologic responses in patients with PTSD. It consisted of reporting trauma information, which is recorded in the form of digital audio. The recording lasted approximately 1.5 minutes and, after this, the patient was instructed to close her eyes and to imagine the traumatic event as vividly as possible for 30 seconds.

**Table 1. Experimental protocol**

<table>
<thead>
<tr>
<th>Day</th>
<th>Phase</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Recruitment</td>
<td>Assistance at the Emergency Department and invitation to participate in study</td>
</tr>
<tr>
<td>1</td>
<td>Selection</td>
<td>Eligibility assessment and signature of the consent form</td>
</tr>
<tr>
<td>2</td>
<td>Pharmacologic intervention (CBD, 300 mg) Behavioral test</td>
<td>Data collection (demographics, STAI-T, STAI-S, PHQ-9, Mini-SMD, SCID-5 [if Mini-SMD results were abnormal])</td>
</tr>
<tr>
<td>2</td>
<td>Pharmacologic intervention (CBD, 300 mg) Behavioral test</td>
<td>Instructions and delivery of material for CAR test</td>
</tr>
<tr>
<td>2-8</td>
<td>Daily treatment with CBD, 300 mg</td>
<td>Collection of samples for the CAR test by the investigator</td>
</tr>
<tr>
<td>2-8</td>
<td>Daily treatment with CBD, 300 mg</td>
<td>Oral administration of CBD, 300 mg, and 2.5 h after performing the behavioral test (described in the text)</td>
</tr>
<tr>
<td>16</td>
<td>Assessment of the pharmacologic intervention on the reconsolidation of traumatic memories</td>
<td>Collection of samples for the CAR test by the investigator</td>
</tr>
<tr>
<td>16</td>
<td>Assessment of the pharmacologic intervention on the reconsolidation of traumatic memories</td>
<td>Measurement of physiologic and psychological (VAMS and STAI-S) correlates of anxiety before and after the behavioral test</td>
</tr>
<tr>
<td>30</td>
<td>Stress disorder evaluation</td>
<td>SCID-5 and PCL-5</td>
</tr>
<tr>
<td>60</td>
<td>Psychiatric evaluation</td>
<td>Collection of samples for the CAR test by the investigator</td>
</tr>
<tr>
<td>60</td>
<td>Psychiatric evaluation</td>
<td>First evaluation for the diagnosis of PTSD (SCID-5)</td>
</tr>
<tr>
<td>180</td>
<td>Psychiatric evaluation</td>
<td>Collection of samples for the CAR test by the investigator</td>
</tr>
<tr>
<td>180</td>
<td>Psychiatric evaluation</td>
<td>Second evaluation for the diagnosis of PTSD (SCID-5)</td>
</tr>
</tbody>
</table>

**Notes:**
- CAR = cortisol awakening response; CBD = cannabidiol; Mini-SMD = Mini-Screening of Mental Disorders; PCL-5 = Posttraumatic Stress Disorder Checklist for DSM-V; PHQ-9 = Patient Health Questionnaire-9; PTSD = posttraumatic stress disorder; SCID-5 = Structured Clinical Interview for the DSM-V; STAI-T = State-Trait Anxiety Inventory-State; STAI-S = State-Trait Anxiety Inventory-Trait; VAMS = Visual Analogue Mood Scales.
Before and after the behavioral test, subjective measures of anxiety (anxiety factor of the Visual Analogue Mood Scales [VAMS]) and data about the physiologic correlates of anxiety (heart rate and systolic and diastolic blood pressure) were recorded. The behavioral testing, which includes reexperiencing of the traumatic event under controlled conditions, is not expected to be detrimental to the patient because a similar procedure is used in the therapeutic technique of extinction.

The administration of CBD, a single dose of 300 mg, started on day 2 before the behavioral test and continued daily for 6 additional days. (Treatment was started in the laboratory on day 2 of the study. After that day, the patient took medication for another 6 days of treatment, totaling 7 days and ending on day 8 of the study.) The patient took the drug orally in the form of capsules containing CBD powder with 99.9% purity dissolved in corn oil (BioSynthesis Pharma Group, Sandwich, UK).

A summary of the experimental protocol and a timeline of the case are presented in Tables 1 and 2, respectively.

**Follow-up and Outcomes**

The patient completed the study protocol until day 180. At baseline (day 1), she had scores of 30 in the STAI-T and 63 in the STAI-S, but the PHQ-9 showed an absence of depressive symptoms.

The results of the anxiety measures before and after the behavioral test are shown in Table 3. After the first CBD administration, the scores of the STAI-S and the anxiety factor of the VAMS increased after the patient recollected the traumatic event, but this increase did not happen 1 week after the end of the 7-day treatment with CBD. The physiologic correlates of anxiety (blood pressure and heart rate) showed discrete and inconsistent changes.

In the first 2 weeks of the study, the score of depressive symptoms assessed with the PHQ-9 increased from 0 to 20. Because of the depressive symptoms, the participant was medicated with sertraline.

In the evaluation performed on day 30, the participant fulfilled DSM-V criteria for acute stress disorder, and on day 60 the criteria were met for PTSD. The score on the PTSD Checklist-5 (intensity of PTSD symptoms) 30 days after the diagnosis of PTSD (180 days of the traumatic event) was 50.

We found an increase in CAR before the pharmacologic intervention and 1 week after the introduction of CBD treatment (day 16; Figure 1). However, this increase in cortisol levels on awakening was attenuated when PTSD developed in the patient (assessments on days 60 and 180).

**DISCUSSION**

In this report, an initial single dose of CBD, 300 mg, failed to prevent an increase in anxiety after recollection of the traumatic event (day 2). However, 1 week after daily administration of CBD for 7 days, reexposure to the account of the traumatic event in the absence of the drug did not increase anxiety scores, suggesting a possible interference of CBD in the reconsolidation of traumatic memories. This suggestion should be considered with caution because this is a single case, even though it is in line with
Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report

preclinical findings in laboratory animals. However, this possible interference in the reconsolidation of aversive memories was not enough to prevent the development of PTSD. It is possible that a single association of CBD with recollection may not be enough in the case of severe trauma, as suggested by a study with caffeine in the reconsolidation of fear memories in rats. In another case report about a 10-year-old patient with PTSD, 12 mg of CBD used as a sublingual spray was able to reduce anxiety and improve sleep quality. A recent retrospective case series, which evaluated the clinical benefit of CBD administration in 11 adults with PTSD, concluded that administration of CBD in oral and spray formulations decreased the symptoms of PTSD. A relevant finding from this study is that CBD substantially decreased nightmare symptoms when assessed by the PTSD Checklist-C in follow-up sessions at 4 and 8 weeks.

The interference of other drugs in the consolidation or reconsolidation of aversive memories has been tested, with propranolol being the most studied. A meta-analysis of these studies with propranolol suggests that its administration before the consolidation or reconsolidation of emotional memories reduces memory with negative valences or the expression of cue-elicited fear.

The main outcome in this case report is related to CAR. Immediately before and 1 week after the pharmacologic intervention with CBD, the usual CAR was observed, with its typical increase on awakening. However, this response was attenuated after PTSD developed (evaluations at 60 and 180 days after the traumatic experience), which corroborates earlier evidence showing that patients with PTSD have an attenuation in CAR compared with healthy controls. Similarly, a systematic review of the literature and meta-analysis examined the psychosocial factors that interfere with CAR in 147 studies and concluded that the presence of PTSD is one of the factors that attenuates CAR. Although this report is based on a single case, it was able to show changes in CAR before and after the onset of PTSD in the same individual. Future studies with larger prospective samples examining different doses of CBD in preventing and treating PTSD are necessary and opportune.

CONCLUSION

Although this case suggested an interference of CBD in reconsolidation, it was not sufficient to prevent the development of PTSD. However, the main observation was a change in CAR in the same patient before and after the start of PTSD towards attenuation.

Disclosure Statement

Antonio Waldo Zuardi, MD, PhD, and José Alexandre Crippa, MD, PhD, are co-inventors of the patent “Fluorinated CBD Compounds, Compositions and Uses thereof” (Publication no. WO2014/108899, International Application No. PCT/BR14/000203; Def. US no. Reg. 62193296 on July 29 2015; and INPI (National Institute of Industrial Property, Brazil) on August 8, 2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytics Inc, Los Angeles, CA (USP [US Pharmacopeia] Resolution no. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi, Toledo, Brazil, to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” José Alexandre Crippa received travel support from Bio-synthesis, Pharmagroup, Sandwich, UK, and is an advisory consultant to the SCBD Center, Sandwich, UK.

The other authors have no conflicts of interest to disclose.

Acknowledgments

José Alexandre Crippa, MD, PhD, received a research grant from University Global Partnership Network, Surrey, UK. Antonio Waldo Zuardi, MD, PhD, and José Alexandre Crippa are recipients of a fellowship award from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Lago Sul, Brazil. The present study was supported by 2 CNPq grants (CNPq/MS/SC/TIE/DECIT N. 26/2014-46680520144 and INCT-CTM). Livia Maria Bolsoni, MS, is the recipient of a doctoral research grant from the São Paulo Research Foundation in São Paulo, Brazil (FAPESP; grant 2016/01801-5).

Kathleen Louden, ELS, of Louden Health Communications performed a primary copy edit.

How to Cite this Article


References

Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report


